Bicara Therapeutics Valuation Multiples

Bicara Therapeutics Overview

About Bicara Therapeutics

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Founded

2018

HQ

Employees

55

Website

bicara.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($157M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Bicara Therapeutics Financials

Bicara Therapeutics reported last 12-month revenue of — and negative EBITDA of ($157M).

In the same LTM period, Bicara Therapeutics generated — in gross profit, ($157M) in EBITDA losses, and had net loss of ($147M).

Bicara Therapeutics P&L

In the most recent fiscal year, Bicara Therapeutics reported revenue of — and EBITDA of ($148M).

Bicara Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

Bicara Therapeutics Stock Performance

Bicara Therapeutics has current market cap of $1B, and enterprise value of $1B.

Bicara Therapeutics' stock price is $21.98.

Bicara Therapeutics Valuation Multiples

Bicara Therapeutics trades at (6.5x) EV/EBITDA.

Bicara Therapeutics Financial Valuation Multiples

As of April 10, 2026, Bicara Therapeutics has market cap of $1B and EV of $1B.

Equity research analysts estimate Bicara Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Bicara Therapeutics has a P/E ratio of (9.8x).

Bicara Therapeutics Margins & Growth Rates

Bicara Therapeutics' revenue in the last fiscal year grew by —.

Bicara Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.8M for the same period.

Bicara Therapeutics Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Bicara Therapeutics M&A Activity

Bicara Therapeutics acquired XXX companies to date.

Last acquisition by Bicara Therapeutics was on XXXXXXXX, XXXXX. Bicara Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Bicara Therapeutics Investment Activity

Bicara Therapeutics invested in XXX companies to date.

Bicara Therapeutics made its latest investment on XXXXXXXX, XXXXX. Bicara Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).